Propanc Biopharma

PPCB - Propanc Biopharma • Financials

Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year
06/2017
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
06/2018
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
06/2019
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
06/2020
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
06/2021
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
06/2022
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
06/2023
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
06/2024
0
-2
-
0%
L
-4
L
1
L
-1
0
1
-1
0
0
-
-
0
-57
-
0%
L
14
L
2
L
-56
0
0
-56
0
0
-
-
0
-18
-
0%
L
9
L
-0
-
-19
-0
6
-19
0
0
-
-